InvestorsHub Logo
Post# of 4966616
Next 10
Followers 0
Posts 578
Boards Moderated 0
Alias Born 04/23/2011

Re: None

Thursday, 01/19/2017 2:29:56 PM

Thursday, January 19, 2017 2:29:56 PM

Post# of 4966616
$OBMP OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) Presents Interesting Picture as a Bite-Size Buyout Candidate

cBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) is in an interesting phase of its existence. The company just solidified its sense of credibility in the space with a recent announcement of a productive meeting with top staffing scientists at the host hospital of the Company’s upcoming Phase 2 trial of ProscaVax for prostate cancer. That represents the first brick in the wall toward some seriously valuable IP.

The company is trading right now at a market cap of just $7.9M, making it practically free for the likes of Eli Lilly and Co (NYSE:LLY), Nymox Pharmaceutical Corporation (NASDAQ:NYMX), or Pfizer Inc. (NYSE:PFE), all of which have been hot on the trail of IP geared toward the prostate cancer market. A price tag under $100M for a viable play into that $7 billion prostate cancer market is a fine starting idea to a conversation among any of these players.

OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) is a clinical stage biopharmaceutical company that develops cancer immunotherapy products. The company has proprietary rights to a breast and prostate patent vaccine; and a process for the growth of cancer cells and targeted chemotherapies. Its lead product is ProscaVax that is in the planning stage of a Phase II clinical trial for the treatment of prostate cancer.

The company also has a portfolio of targeted therapies. OncBioMune Pharmaceuticals, Inc. is headquartered in Baton Rouge, Louisiana.
Target Acquired

As noted above, there are a number of recent deals in the biotech space that suggest bigger players are currently very much in the hunt for targets that leap them forward in a variety of R&D pathways. Hill-Rom Holdings, Inc. (NYSE:HRC) recently paid $330M for Mortara. We also just saw Celgene Corporation (NASDAQ:CELG) take Anokion off the playing field. In similar fashion, and right up our current alley, Pfizer just scooped up Medivation Inc (NASDAQ:MDVN) primarily for their IP related to the prostate cancer market.

https://wallstreetpr.com/oncbiomune-pharmaceuticals-inc-otcmktsobmp-presents-interesting-picture-as-a-bite-size-buyout-candidate-37725

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.